Genetically modifying autologous T cells to express chimeric antigen receptors (CARs), thus redirecting them to eliminate tumor cells, is a new and revolutionary therapeutic modality for cancer treatment and, in particular, for CD19+ B cell malignancies.1, 2, 3, 4, 5, 6, 7, 8, 9. Here, CD19 is linked to neoplasm.